BioNTech has shown why it made small cell lung cancer (SCLC) a priority for its PD-L1xVEGF-A bispecific. | BioNTech has shown ...
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
Treatment with CAN-2409, an off-the-shelf immunotherapy, elicited responses among patients with pretreated stage 3/4 ...
Pembrolizumab and concurrent CRT, followed by pembrolizumab consolidation, provided long-term tumor control in previously untreated, unresectable, stage III NSCLC.
Emerging data suggest that SBRT may be comparable with surgery for definitive treatment of stage I NSCLC in certain patients. When is one approach preferred and in whom?
The latest data from Johnson and Johnson's Rybrevant and Lazcluze lung cancer combo was better than standard of care Tagrisso ...
An application was submitted to the European Medicines Agency seeking approval for treatment with sugemalimab in stage 3 ...
New study results presented at the European Lung Cancer Congress (ELCC) 2025, March 26 to 29, demonstrate the role of AstraZeneca’s TAGRISSO® (osimertinib), as monotherapy and as the backbone for ...
Annual lung cancer screening, or LCS, detects cancer at a higher rate and at earlier stages, findings suggest.According to Roger Y. Kim, MD, MSCE, DAABIP, ATSF, an assistant professor of medicine at ...
BNT327 combined with chemotherapy showed an overall response rate of 85.4% when used as a first-line treatment for ...
Checkmate 816 established chemoimmunotherapy as the standard of care neoadjuvant treatment for resectable stage ... phase III trial schema. ECOG PS, Eastern Cooperative Oncology Group performance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback